Overview: Mycoplasma Pneumoniae IgM TestIntroduction: The Mycoplasma Pneumoniae IgM Test detects Mycoplasma IgM to diagnose recent infection, causing pneumonia or sore throat. Following 2023 IDSA guidelines, it uses immunoassay for high specificity, supporting infection screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in serology for patients with suspected acute Mycoplasma pneumoniae infection.
Other Names: Mycoplasma IgM Assay, Recent Mycoplasma Test.
FDA Status: Laboratory-developed test (LDT), meeting serology standards for diagnostic accuracy.
Historical Milestone: Mycoplasma IgM testing began in the 1970s with pneumonia research. Immunoassay methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects Mycoplasma IgM to diagnose recent infection, guides treatment, and evaluates patients with pneumonia or sore throat.
Test Parameters: 1. Mycoplasma Pneumoniae IgM Antibodies
Pretest Condition: No fasting required. Collect serum or saliva. Report history of pneumonia, sore throat, or Mycoplasma exposure.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document pneumonia, sore throat, cough, or Mycoplasma exposure. Include current medications, especially antibiotics.
Consent: Written consent required, detailing the tests purpose, Mycoplasma infection implications, and risks of sample collection.
Procedural Considerations: Uses immunoassay to detect Mycoplasma IgM in serum or saliva. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for acute Mycoplasma diagnosis.
Factors Affecting Result Accuracy: Hemolysis, lipemia, or improper sample storage can affect results. Early infection may yield false negatives.
Clinical Significance: Positive Mycoplasma IgM confirms recent infection, guiding antibiotic therapy (e.g., azithromycin). Negative results may require PCR testing.
Specialist Consultation: Consult an infectious disease specialist or pulmonologist for result interpretation and treatment planning.
Additional Supporting Tests: Mycoplasma PCR, IgG test, or chest X-ray to confirm Mycoplasma diagnosis.
Test Limitations: Early infection may yield false negatives; clinical correlation is needed. Cross-reactivity with other pathogens may occur.
References: IDSA Mycoplasma Guidelines, 2023; Clinical Infectious Diseases, Waites KB, 2022.
